All In Biotech

Drug Trial Radar · NCT00506415

Comparative Efficacy, Safety, and Tolerability of Rivastigmine 10 and 15 cm^2 Patch in Patients With Alzheimer's Disease (AD) Showing Cognitive Decline

A 48-Week, Multicenter, Randomized, Double-Blind, Parallel-Group Evaluation of the Comparative Efficacy, Safety, and Tolerability of Exelon® 10 and 15 cm^2 Patch in Patients With Mild to Moderate Alzheimer's Disease (AD) Showing Functional and Cognitive Decline

Last checked: Nov 20, 2026Latest source record: Sep 19, 2012 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 1,584 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

1,584

Actual

Start

Jun 2007

Primary completion

May 2011

Study completion May 2011

Sponsor

Lead sponsor
Novartis PharmaceuticalsNovartis (NVS)
Sponsor type
Industry
First posted
Jul 25, 2007

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, care provider, investigator)
Primary purpose
Treatment
Who can join
All sexes, from 50 years, up to 85 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study was to support the optimal use of rivastigmine patch in long-term treatment of Alzheimer's Disease in patients demonstrating functional and cognitive decline at the target maintenance dose of rivastigmine patch 10 cm\^2.

Conditions

  • Alzheimer Disease

Interventions

  • Rivastigmine 5 cm^2Drug

    5 cm\^2 transdermal patch

  • Rivastigmine 10 cm^2Drug

    10 cm\^2 transdermal patch.

  • Rivastigmine 15 cm^2Drug

    15 cm\^2 transdermal patch.

  • Placebo to 15 cm^2 patchDrug

    Placebo of rivastigmine transdermal patch 15 cm\^2.

  • Placebo to 10 cm^2 patchDrug

    Placebo of rivastigmine transdermal patch 10 cm\^2.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change From Baseline in Alzheimer's Disease Assessment Scale-Cognitive (ADAS-Cog) Subscale at Week 48 of Double Blind PeriodTime frame: Baseline and week 48 of double blind period
  2. Change in Alzheimer's Disease Cooperative Study-Instrumental Activities of Daily Living (ADCS-IADL) Subscale Score From Baseline to Week 48 of Double Blind PeriodTime frame: Baseline and week 48 of double blind period

Locations

145 sites in 7 countries. Site status is shown where the registry gives one.

  • Novartis investigative site

    Birmingham, Alabama

  • Novartis investigative site

    Gilbert, Arizona

  • Novartis investigative site

    Phoenix, Arizona

  • Novartis investigative site

    Sun City, Arizona

  • Novartis investigative site

    Anaheim, California

  • Novartis investigative site

    Carson, California

  • Novartis investigative site

    Costa Mesa, California

  • Novartis investigative site

    Fullerton, California

  • Novartis investigative site

    La Habra, California

  • Novartis investigative site

    La Jolla, California

  • Novartis investigative site

    National City, California

  • Novartis investigative site

    Redlands, California

  • Novartis investigative site

    San Francisco, California

  • Novartis investigative site

    Fort Collins, Colorado

  • Novartis investigative site

    Longmont, Colorado

  • Novartis investigative site

    Boca Raton, Florida

  • Novartis investigative site

    Bradenton, Florida

  • Novartis investigative site

    Deerfield Beach, Florida

  • Novartis investigative site

    Delray Beach, Florida

  • Novartis investigative site

    Fort Lauderdale, Florida

  • Novartis investigative site

    Gainesville, Florida

  • Novartis investigative site

    Miami Beach, Florida

  • Novartis investigative site

    Pompano Beach, Florida

  • Novartis investigative site

    Port Charlotte, Florida

  • Novartis investigative site

    Sunrise, Florida

  • Novartis investigative site

    West Palm Beach, Florida

  • Novartis investigative site

    Atlanta, Georgia

  • Novartis investigative site

    Macon, Georgia

  • Novartis Investigative Site

    Honolulu, Hawaii

  • Novartis investigative site

    Chicago, Illinois

  • Novartis investigative site

    Springfield, Massachusetts

  • Novartis investigative site

    Flint, Michigan

  • Novartis investigative site

    Flushing, Michigan

  • Novartis investigative site

    Roseville, Michigan

  • Novartis investigative site

    Traverse City, Michigan

  • Novartis investigative site

    Hattiesburg, Mississippi

  • Novartis investigative site

    Ocean Springs, Mississippi

  • Novartis investigative site

    Columbia, Missouri

  • Novartis investigative site

    St Louis, Missouri

  • Novartis investigative site

    Flemington, New Jersey

Showing 40 of 145 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.